STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more

STAT PlusNewsletterPharmalot Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more Combination of pancreatic cancer drugs from Tango and Revolution leads to a high response rate Manage alerts for this article Email this article Share this article By Ed SilvermanJune 8, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and the like has returned with a vengeance. You knew this would happen, yes? To cope, we are relying, as always, on cups of stimulation. Our choice today is laced with chocolate raspberry. Feel free to join us. Remember, no prescription is required. Meanwhile, here are some tidbits to help you along. Best of luck accomplishing your goals today, and of course, do keep in touch. … Revolution Medicines’ experimental pancreatic cancer drug has been the star of the oncology field in recent weeks, with new data showing the medicine produced unprecedented outcomes for patients, but its next act — this time as a co-lead — was just revealed, STAT points out. Tango Therapeutics said that in an early-stage clinical trial, a combination of its drug vopimetostat and Revolution’s daraxonrasib led to durable responses in the large majority of pancreatic cancer patients who received both medicines. Tango’s strategy of testing the two targeted drugs is notable because combination approaches in pancreatic cancer often include chemotherapy. The recent successful Revolution trial that has upended the specialty tested daraxonrasib versus chemotherapy as a second-line treatment. Advertisement Eli Lilly has already established that its next-generation obesity drug can lead to rapid weight loss, but researchers disclosed new data that provide more details on the safety and tolerability of the closely watched therapy, STAT writes. Lilly previously said that in one late-stage study, retatrutide helped people with diabetes lower blood sugar and lose a significant amount of weight, which is notable since those who have diabetes tend to lose less weight on treatment than those who do not. New data showed seven out of the 403 participants who received retatrutide experienced arrhythmias, and three treated participants experienced major cardiovascular complications, compared with none in the placebo group. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In pharmalittle, STAT+ Submit a correction requestReprints Ed Silverman Pharmalot Columnist, Senior Writer Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended Pharmalot June 5, 2026 STAT Plus: Up and down the ladder: The latest comings and goings Pharmalot June 5, 2026 STAT Plus: Pharmalittle: We’re reading about Roche accusing U.S. of ‘blackmail,’ a ruling on skinny labels, and more Advertisement Pharmalot June 4, 2026 STAT Plus: Supreme Court backs generic drugmaker in ‘skinny labeling’ case Pharmalot June 4, 2026 STAT Plus: For pancreatic cancer patients, an exciting drug can feel out of reach Pharmalot June 4, 2026 STAT Plus: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and more Subscriber Picks